Article info
PDFRecent advances in clinical practice
Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists
- Correspondence to Professor Giovanni Targher, Metabolic Diseases Research Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Veneto, Italy; giovanni.targher{at}univr.it
Citation
Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists
Publication history
- Received October 3, 2024
- Accepted November 3, 2024
- First published November 26, 2024.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.